8.36

6.91% +0.54

After Hours: 8.47 0.11 +1.32%

Voyager Therapeutics Inc (VYGR)

Overview News Price History Option Chain Discussions Forecast

Voyager Therapeutics Inc stock is currently priced at $8.36, with a 24-hour trading volume of 610.12K. It has seen a +6.91% increased in the last 24 hours and a -20.68% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $7.77 pivot point. If it approaches the $8.15 resistance level, significant changes may occur.

Previous Close:

$7.82

Open:

$7.8

24h Volume:

610.12K

Market Cap:

$454.69M

Revenue:

$250.01M

Net Income/Loss:

$132.33M

P/E Ratio:

3.6828

EPS:

2.27

Net Cash Flow:

$74.66M

1W Performance:

+10.44%

1M Performance:

-20.68%

6M Performance:

+27.63%

1Y Performance:

+15.47%

1D Range:

$7.80

$8.56

52W Range:

$6.06

$14.34

Voyager Therapeutics Inc Stock (VYGR) Company Profile

Name

Voyager Therapeutics Inc

Sector

Healthcare (1189)

Industry

Biotechnology (685)

Phone

857-259-5340

Address

75 Sidney Street, Cambridge, MA

Employee

Twitter

@VoyagerTx

Next Earnings Date

2024-05-07

Latest SEC Filings

VYGR's Discussions on Twitter

Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-10-23	Initiated	Truist	Buy
Mar-10-23	Initiated	Oppenheimer	Outperform
Oct-07-21	Upgrade	Robert W. Baird	Neutral → Outperform
Feb-26-21	Downgrade	Robert W. Baird	Outperform → Neutral
Feb-03-21	Downgrade	BTIG Research	Buy → Neutral
Feb-03-21	Downgrade	Wedbush	Outperform → Neutral
Dec-24-20	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Dec-23-20	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-11-20	Downgrade	Oppenheimer	Outperform → Perform
Nov-10-20	Downgrade	Raymond James	Strong Buy → Outperform
Nov-10-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Mar-19-20	Initiated	The Benchmark Company	Buy
Feb-06-20	Initiated	Oppenheimer	Outperform
Nov-15-18	Upgrade	Raymond James	Outperform → Strong Buy
Sep-10-18	Resumed	BTIG Research	Buy
Sep-10-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-04-18	Initiated	H.C. Wainwright	Buy
Mar-12-18	Downgrade	Evercore ISI	Outperform → In-line
Mar-12-18	Downgrade	Wedbush	Outperform → Neutral
Feb-02-18	Initiated	Morgan Stanley	Overweight
Nov-28-17	Resumed	Piper Jaffray	Overweight
Oct-31-17	Initiated	Robert W. Baird	Outperform
Oct-27-17	Initiated	Canaccord Genuity	Buy
Oct-23-17	Reiterated	Stifel	Buy
Oct-12-17	Initiated	Raymond James	Outperform
Aug-17-17	Initiated	Evercore ISI	Outperform
Jul-28-17	Resumed	Stifel	Buy

View All

Voyager Therapeutics Inc Stock (VYGR) Latest News

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

GlobeNewswire Inc.

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

GlobeNewswire Inc.

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Voyager Therapeutics Inc Stock (VYGR) Financials Data

Voyager Therapeutics Inc (VYGR) Revenue 2024

VYGR reported a revenue (TTM) of $250.01 million for the quarter ending December 31, 2023, a +511.18% rise year-over-year.

Voyager Therapeutics Inc (VYGR) Net Income 2024

VYGR net income (TTM) was $132.33 million for the quarter ending December 31, 2023, a +385.14% increase year-over-year.

Voyager Therapeutics Inc (VYGR) Cash Flow 2024

VYGR recorded a free cash flow (TTM) of $74.66 million for the quarter ending December 31, 2023, a +597.75% increase year-over-year.

Voyager Therapeutics Inc (VYGR) Earnings per Share 2024

VYGR earnings per share (TTM) was $3.03 for the quarter ending December 31, 2023, a +348.36% growth year-over-year.

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease. Its preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program, for tauopathies, including Alzheimer's disease, PSP, and FTD; and VY-NAV01 for severe chronic pain. The company has strategic collaboration agreement with AbbVie Inc.; Sanofi Genzyme; the University of Massachusetts; and MRI Interventions, Inc., as well as has collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.